Presenter: Chivonne Harrigal, MD
Online CME Credit
Fee: $50.00
Recorded virtual program while following all state and county guidelines at the time of recording, August 19, 2020.
Provides 1.00 hour of CE/CME credit (Presented on Aug 19, 2020; Reviewed November 1, 2022; Expires November 1, 2023)
This series is intended to address Nevada's low cancer screening rates and decrease the number of late-stage diagnoses.
Following participation in this course, participants should be able to:
For questions concerning the online evaluation or your certificate, please contact our office at (775) 784-4791 or email us at cme@med.unr.edu.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the Nevada Cancer Coalition. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nevada, Reno School of Medicine approves this program for 1.00 hour of nursing continuing education credit.
As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada, Reno School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, The University of Nevada, Reno School of Medicine requires that anyone in a position to control or influence the content of an accredited activity disclose all financial relationships within the prior 24 months with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. All relevant financial relationships have been mitigated. Following are those disclosures.
All other presenters, planners or anyone in a position to control the content of this continuing medical education activity have indicated that they do not have financial relationships with ineligible companies related to the content of this activity.
American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc. 2019.
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792
DeSantis, CE et al Breast Cancer Statistics, 2019. CA Cancer J Clin 2019;69:438-451. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst. 2013;105:515-525.
Hendrick, Helvie. AJR 2011; 196:W112-W116
Kohler B, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.
Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469-8476.
Mainiero MB, Lourenco A, Mahoney MC, Newell MS, et al., ACR Appropriateness Criteria breast cancer screening., Journal of the American College of Radiology, 13 (11S), NA, November 2016.
Mandelblatt, et al. Ann Intern Med. 2009 Nov 17; 151 (10) 738-747.
National Comprehensive Cancer Network. Guidelines for Breast Cancer Screening and Diagnosis. Version 2.2019 http://www.NCCN.org Oeffinger et al. JAMA. 2015 Oct 20; 314(15): 1599-161
Tabar et al, Radiol 2012; 260:658-663
Tamimi RM, Spiegelman D, Smith-Warner SA, et al. Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal
Breast Cancer. Am J Epidemiol. 2016;184(12):884-893.
Torre LA, Bray F, Siegel RL, Ferlay J, Loretta-Tieulent J, Jamal A. Global Cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87-108.
Welch, G.H. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness NEJM 2016; 375:1438-47.